Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal! AI is eating the world—and the machines behind it are ravenous. Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy. In fact, AI is already pushing global power grids to the brink. Wall Street is pouring hundreds of billions into artificial intelligence—training smarter chatbots, automating industries, and b ...

Market Performance - The U.S. stock market showed strong performance last week, with major indices like the S&P 500, Nasdaq Composite, and Dow Jones Industrial Average increasing by 0.82%, 0.84%, and 0.96% respectively [1] - Investor optimism was fueled by advancements in Artificial Intelligence and expectations for further interest rate cuts by the Federal Reserve, despite a partial government shutdown creating uncertainties [1] Consumer Confidence and Labor Market - The Conference Board's Consumer Confidence Index for September dropped by 3.6 points to 94.2, marking its lowest level since April, attributed to inflation and a weakening job market [2] - Job openings increased slightly by 19,000 to 7.227 million in August, while hiring decreased by 114,000 to 5.126 million according to the Job Openings and Labor Turnover Survey [2] Zacks Research Performance - Amneal Pharmaceuticals saw a stock increase of 29.9% since its Zacks Rank upgrade on July 25, outperforming the S&P 500's 5.5% increase [4][7] - Leidos Holdings experienced a 19.8% return following a Zacks Rank upgrade on July 28, also surpassing the S&P 500's 5.1% increase [5][7] - A hypothetical portfolio of Zacks Rank 1 stocks returned +8.64% in 2025 through September 1, compared to +7.60% for the S&P 500 index [5] Focus List and Model Portfolios - The Zacks Focus List portfolio returned 13.74% in 2025 through August 31, outperforming the S&P 500 index's 10.79% [12] - Intellia Therapeutics gained 85.9% and Shopify returned 38.3% over the past 12 weeks, significantly outperforming the S&P 500's 7% increase during the same period [11] Earnings Certain Admiral Portfolio (ECAP) - The ECAP returned +0.20% in Q2 2025, underperforming the S&P 500 index's +10.94% gain [16] - The portfolio aims to minimize capital loss by holding shares of companies with a proven track record of earnings stability over 20+ years [17] Earnings Certain Dividend Portfolio (ECDP) - Johnson & Johnson returned 20.9% and Home Depot increased by 6.3% over the past 12 weeks, benefiting from investor preference for quality dividend stocks amid market volatility [19] - The ECDP returned -3.17% in Q2 2025, compared to the S&P 500 index's +10.94% gain [20] Top 10 Stocks Performance - Goldman Sachs, part of the Zacks Top 10 Stocks for 2025, increased by 38% year-to-date, outperforming the S&P 500 index's 14.2% increase [22] - The Top 10 portfolio has produced a cumulative return of +2,369.7% since 2012, significantly outperforming the S&P 500 index's 522.5% [24]

The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current market environment may also lie in its non-cyclical nature, thanks to resilient demand that is more related to health needs and demographics than to external economic conditions. However, finding healthcare names poised for major growth may be difficult, considering that many of the largest legacy firms in the spac ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Amneal Pharmaceuticals, Inc. is one of them. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) continues to strengthen its position in generic, branded, and specialty medicines, marking September 2025 with key regulatory milestones and financial progress. On September 26, AMRX submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR® (omalizumab), targeting a multi-billion-dollar market that includes asthma, c ...

BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com ...

Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for AmnealBRIDGEWATER, N.J., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for a proposed biosimilar to XOLAIR® (omalizumab), developed by Kashiv BioSciences, LLC. XOLAIR® is a registered trademark of Novartis AG. Omalizumab, a humanized ...

BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Abbreviated New Drug Application (ANDA) for bimatoprost ophthalmic solution 0.01% (2.5 mL, 5 mL and 7.5 mL). The product is the generic equivalent of LUMIGAN® (bimatoprost ophthalmic solution) 0.01%, whose design is a trademark of Allergan, Inc., an AbbVie company. Bimatoprost ophthalmic solution 0.01% is a ...

Core Viewpoint - Amneal Pharmaceuticals received FDA approval for its generic version of Jazz Pharmaceuticals' sleep disorder therapy Xyrem, allowing market entry for the product [2] Company Summary - Amneal Pharmaceuticals' Abbreviated New Drug Application (ANDA) has been approved by the FDA, enabling the launch of its generic product [2]

Core Insights - Amneal Pharmaceuticals has received FDA approval for its sodium oxybate oral solution 500 mg/mL, expanding its Affordable Medicines portfolio and providing a more affordable alternative for narcolepsy treatment [1][3]. Company Overview - Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a diverse portfolio of over 280 pharmaceuticals, primarily in the U.S. [4]. - The company operates in various segments, including Affordable Medicines, Specialty, and AvKARE, focusing on complex product categories and therapeutic areas [4]. Product Details - Sodium oxybate is a central nervous system depressant used to treat cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy [2]. - The approval of sodium oxybate oral solution addresses a critical therapy area for approximately 150,000 individuals in the U.S. living with narcolepsy [3]. Market Impact - The introduction of sodium oxybate by Amneal is significant as it provides patients, providers, and payers with a more affordable option in a market historically dominated by a single manufacturer [3].

Core Insights - Albert Anthony is a Croatian-American business author and media contributor with a focus on real estate investment trusts (REITs) [1] - He has a background in IT analysis for Fortune 500 companies and experience in financial services with Charles Schwab [1] - Anthony is launching a book on REITs in 2025 and operates his own equities research firm remotely [1] Background and Experience - The author has participated in numerous business and innovation conferences in the EU and has a strong educational background, including degrees from Drew University [1] - He is currently pursuing the CMSA certification at the Corporate Finance Institute in Vancouver [1] - Anthony has also been involved in digital media, including a YouTube channel focused on REITs [1] Professional Focus - The firm does not engage with non-publicly traded companies, small-cap stocks, or startup CEOs [1] - Albert Anthony & Company provides general market commentary and research based on publicly available data [1] - The author does not hold material positions in any stocks rated at the time of writing unless disclosed [1]